With Zero 483 observations
Caplin Point Laboratories announced that the United States Food and Drug Administration (US FDA) has conducted an inspection at its Sterile Injectable Site (CP - IV) located at Gummudipoondi from 30 August 2018 to 06 September 2018.This was a scheduled inspection and at the end of the inspection, there were ZERO 483s
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
